Multicenter Registry Study on the Effectiveness of Drug Switch for Diabetic Macular Edema

Effect of Drug Switch on Diabetic Macular Edema - Effect of Drug Switch on Diabetic Macular Edema

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055623

Enrollment

500

Registered

2024-09-26

Start date

2024-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients on anti-VEGF therapy for DME who switched to another anti-VEGF agent (currently there are a total of six approved anti-VEGF agents: Lucentis Airea, ranibizumab-BS, Babiesumo Beobuy Airea 8 mg).

Exclusion criteria

Exclusion criteria: Cases in which the patient has expressed his/her refusal to be registered Cases in which the patient withdraws consent Patients who need to give their consent

Design outcomes

Primary

Measure	Time frame
Indications for Anti-VEGF Drug Switch for DME and Changes in Visual Function and Imaging Findings	—

Secondary

Measure	Time frame
Correlation analysis between surgical procedures and findings and the course of visual function after treatment	—

Countries

Japan

Contacts

Public ContactMasahiko Sugimoto

Faculty of Medicine, Yamagata University. Department of Ophthalmology and Visual Science,

sugmochi92@gmail.com023-628-5374

Outcome results